The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
The mass spec-based assay can detect viral proteins eight days after the onset of symptoms, compared to four to five days with PCR tests, its developers said.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
